89Zr-DFO-huJ591 PET Scan for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new type of scan to see if it can better detect prostate cancer that has spread, especially to the bones. The scan uses a special substance to highlight cancer cells in the body. Researchers hope this will improve future cancer treatments.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study doctors to get a clear answer.
Is 89Zr-DFO-huJ591 safe for use in humans?
In studies involving 89Zr-DFO-huJ591 for prostate cancer imaging, the treatment was generally well-tolerated, with the kidneys being the most exposed organ to radiation. The effective radiation dose was considered manageable, but the potential benefits should be weighed against the radiation exposure.12345
How is the 89Zr-DFO-huJ591 PET scan treatment different from other prostate cancer treatments?
What data supports the effectiveness of the treatment 89Zr-DFO-huJ591 for prostate cancer?
Who Is on the Research Team?
Michael Morris, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for adult males over 18 with confirmed prostate cancer at MSKCC, showing disease progression either through scans or rising PSA levels. Participants must have a performance status of 60+ on the Karnofsky scale and be able to consent. Men who've had anaphylactic reactions to J591 or FDG, or those with certain abnormal liver test results are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Scans
Participants undergo a baseline FDG PET scan up to 14 days before administration of the 89Zr-DFO-huJ591 tracer
Treatment
Administration of a single dose of the 89Zr-DFO-huJ591 tracer followed by multiple PET scans to assess pharmacokinetics and biodistribution
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- 89Zr-DFO-huJ591
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Broad Institute of MIT and Harvard
Collaborator
Weill Medical College of Cornell University
Collaborator
Broad Institute
Collaborator